All Posts By

Smartkarma Daily Briefs

Daily Brief Japan: Hogy Medical, Strike, Hokkoku Financial Holdings, Mitsubishi Kakoki Kaisha, Itochu Enex, Jcr Pharmaceuticals, Kanematsu Corp, Logizard, Meiwa Corp, Olba Healthcare Holdings and more

By | Daily Briefs, Japan

In today’s briefing:

  • Hogy (3593 JP): Can Activism Alone Save Hogy From Going Down a Spriral? Fundamentals Don’t Support
  • Strike (6196 JP): Full-year FY09/25 flash update
  • Hokkoku Financial Holdings (7381 JP): 1H FY03/26 flash update
  • Mitsubishi Kakoki Kaisha (6331 JP): 1H FY03/26 flash update; revised full-year forecast
  • Itochu Enex (8133 JP): 1H FY03/26 flash update
  • JCR Pharmaceutical (4552 JP): Licensing Income Boosts H1FY26 Overall Performance; What Lies Ahead
  • Kanematsu Corp (8020 JP): 1H FY03/26 flash update
  • (30 Oct 2025) Logizard(4391 JP) — Fisco Company Research
  • Meiwa Corp (8103 JP): 1H FY03/26 flash update
  • Olba Healthcare Holdings (2689 JP): Q1 FY06/26 flash update


Hogy (3593 JP): Can Activism Alone Save Hogy From Going Down a Spriral? Fundamentals Don’t Support

By Tina Banerjee

  • Hogy Medical (3593 JP) , in the last 10 fiscals, witnessed sales grow at CAGR of 1%. In tandem with that, company reported 4% drop sales to ¥18.9B in H1FY26.
  • The company revised FY26 sales guidance downwards to ¥39.2B (from previous ¥41.8B), with profits also witnessing considerable downward revision.
  • Stock to underperform and so we recommend a SELL on Hogy at this moment. Strategically, two possible outcomes open for Hogy, a take-over by another corporate entity or going private.

Strike (6196 JP): Full-year FY09/25 flash update

By Shared Research

  • FY09/25 revenue was JPY20.3bn (+12.0% YoY), with operating profit at JPY6.3bn (-6.5% YoY) and net income JPY4.7bn (-4.7% YoY).
  • Strike forecasts FY09/26 revenue of JPY24.3bn (+19.8% YoY) and operating profit of JPY8.4bn (+32.2% YoY).
  • The company plans an annual dividend of JPY180.0 per share, maintaining a payout ratio of 60.2%.

Hokkoku Financial Holdings (7381 JP): 1H FY03/26 flash update

By Shared Research

  • Consolidated ordinary income increased by 19.6% YoY to JPY53.7bn, driven by higher interest and dividend income.
  • Hokkoku Bank’s core gross profit grew 23.9% YoY to JPY24.5bn, with a 50.0% rise in core operating profit.
  • Non-performing loans at Hokkoku Bank totaled JPY78.3bn, with a 0.25pp YoY decline in percentage of total credit.

Mitsubishi Kakoki Kaisha (6331 JP): 1H FY03/26 flash update; revised full-year forecast

By Shared Research

  • The company reported a 35.7% YoY revenue increase to JPY36.1bn and a 65.4% YoY rise in operating profit.
  • Revised full-year FY03/26 forecast: revenue JPY88.5bn, operating profit JPY8.6bn, recurring profit JPY8.7bn, net income JPY5.9bn.
  • Engineering segment revenue rose 25.8% YoY, with a 1,201.4% surge in operating profit, OPM at 4.6%.

Itochu Enex (8133 JP): 1H FY03/26 flash update

By Shared Research

  • In Q2 FY03/26, Itochu Enex reported sales revenue of JPY411.7bn, operating profit of JPY11.2bn, and net profit of JPY6.9bn.
  • Car-Life Division’s sales revenue was JPY289.26bn, with operating profit down 39.8% YoY, and net profit down 29.8% YoY.
  • Industrial Business Division’s sales revenue was JPY55.3bn, operating profit up 7.5% YoY, and net profit up 10.9% YoY.

JCR Pharmaceutical (4552 JP): Licensing Income Boosts H1FY26 Overall Performance; What Lies Ahead

By Tina Banerjee

  • Jcr Pharmaceuticals (4552 JP) has reported in-line performance for H1FY26. While mainstay product is facing pricing and competitive pressure, one-off licensing income has driven overall performance.   
  • JCR is expected to meet FY26 guidance. H1FY26 sales, operating profit, and net profit represent progress rate of 56.5%, 91.5%, and 57.0%, against full-year guidance, respectively.
  • Heavy dependence on one major product, which is subject to pricing and competitive pressure, and no major product launch lined up anytime soon are key near-term risks.

Kanematsu Corp (8020 JP): 1H FY03/26 flash update

By Shared Research

  • Companywide revenue decreased by 1.0% YoY, while profit attributable to owners increased by 6.6% YoY.
  • Strong performance in mobile and ICT segments boosted profits, despite declines in iron, steel, and energy.
  • Equity ratio attributable to owners was 28.3%, with net interest-bearing debt-to-equity ratio at 0.59x.

(30 Oct 2025) Logizard(4391 JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • Logizard Co., Ltd. reported a 10.1% increase in net sales to ¥2,177 million and a 17.8% rise in operating profit to ¥408 million for FY6/25, driven by cloud services.
  • The company focuses on inventory management systems for retail and logistics, offering subscription-based solutions like Logizard ZERO and Logizard OCE.
  • For FY6/26, Logizard expects a 12.1% increase in net sales but a decline in operating profit due to investments, aiming for significant growth by FY6/28.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


Meiwa Corp (8103 JP): 1H FY03/26 flash update

By Shared Research

  • Revenue decreased 1.8% YoY; operating profit rose 44.6% YoY; recurring profit increased 20.5% YoY; net income grew 14.5% YoY.
  • Meiwa’s FY03/26 forecast: revenue JPY160.0bn (+2.1% YoY), operating profit JPY3.2bn (-10.3% YoY), recurring profit JPY4.0bn (-11.5% YoY).
  • Meiwa plans a JPY38.00 per share dividend for FY03/26, reflecting lower net income expectations.

Olba Healthcare Holdings (2689 JP): Q1 FY06/26 flash update

By Shared Research

  • The company’s Q1 FY06/26 sales were JPY30.8bn (+6.1% YoY), with operating profit at JPY259mn (-7.3% YoY).
  • Medical Devices and Consumables segment sales rose 5.2% YoY, driven by consumables and equipment sales growth.
  • SPD segment sales increased 6.3% YoY, but operating profit declined 31.4% YoY due to rising SG&A expenses.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Energy/Materials: LG Chem Ltd, SK Innovation, Natural Gas, SGX Rubber Future TSR20, Hindalco Industries, 88 Energy Ltd, DuPont, Ercros , Yunnan Yuntianhua Co A, BP PLC and more

By | Daily Briefs, Energy & Materials Sector

In today’s briefing:

  • LG Chem: Considering Higher Dividend Payout Using Sale Proceeds from LGES
  • SK Innovation – End of Lockup Period For 33% of Outstanding Shares
  • When the Boom Bites Back: How a Global LNG Surge Could Reshape U.S. Gas Markets
  • Rising Domestic Pull And Price Strength Reshape Cambodian Rubber
  • India Finally Showing Signs of Life; Remain Overweight Taiwan, China, Korea, and the U.S.
  • Primer: 88 Energy Ltd (88E AU) – Oct 2025
  • DuPont De Nemours, Inc. (NYSE: DD) To Separate Its Electronics Business on Nov 1
  • Ercros: Regulatory Green Light, Shareholder Hurdles Ahead
  • Primer: Yunnan Yuntianhua Co A (600096 CH) – Oct 2025
  • bp — bp updates Bumerangue


LG Chem: Considering Higher Dividend Payout Using Sale Proceeds from LGES

By Douglas Kim

  • LG Chem is considering on paying higher dividends using sale proceeds from LG Energy Solution. 
  • This breaks the company’s principle of using only ordinary income from operating activities as a source for dividends.
  • If indeed LG Chem goes ahead with this plan, this would be as a result of heightened demands from major activist investors including Palliser Capital.

SK Innovation – End of Lockup Period For 33% of Outstanding Shares

By Douglas Kim

  • There is an end of a lock-up period for 55.3 million shares (33% of outstanding shares) for SK Innovation (096770 KS) starting 20 November 2025.
  • This could potentially result in additional selling by insiders which could negatively impact its share price in the coming weeks.
  • SK Innovation is currently trading at relatively high valuation multiples. We remain Bearish on SK Innovation.

When the Boom Bites Back: How a Global LNG Surge Could Reshape U.S. Gas Markets

By Suhas Reddy

  • Henry Hub prices are rising ahead of a colder U.S. winter, but stronger domestic production and expanding LNG exports could temper the pace of seasonal gains.
  • Global LNG capacity is set to soar by 60% by 2030, raising the risk of a supply glut that could depress international gas prices and challenge U.S. competitiveness.
  • While global LNG oversupply may pressure prices abroad, surging AI-driven electricity demand and slower renewable deployment could lift domestic gas consumption and keep prices resilient.

Rising Domestic Pull And Price Strength Reshape Cambodian Rubber

By Vinod Nedumudy

  • Export volumes fall, but revenues hold firm on higher prices  
  • Domestic latex consumption surges 89%, reshaping local demand base  
  • Chinese investments deepen industrial linkages and energy synergy

India Finally Showing Signs of Life; Remain Overweight Taiwan, China, Korea, and the U.S.

By Joe Jasper

  • We remain near-term bullish since our 4/22/25 Compass, and our intermediate-term outlook remains bullish as well (as of our 5/14/25 Compass), with Int’l Compass reports all echoing this sentiment.
  • In our prior Int’l Compass (Oct. 16) we discussed how the pullback was testing the uptrend, and we were buyers; this worked out well with indexes back at all-time highs.
  • Taiwan, China, Korea, and the U.S. remain our only overweights, but India is becoming more attractive as well — add selective exposure. Many buy ideas highlighted in these countries.

Primer: 88 Energy Ltd (88E AU) – Oct 2025

By αSK

  • 88 Energy is a high-risk, high-reward oil and gas exploration company with a primary focus on large-scale, early-stage projects in the politically stable and well-developed hydrocarbon province of Alaska’s North Slope.
  • The company’s strategy centers on identifying and de-risking significant prospective resources and then farming out interests to larger partners to fund capital-intensive drilling and development, thereby minimizing shareholder dilution and financial risk.
  • Recent divestment from production assets in Texas has sharpened the company’s focus on its core Alaskan exploration portfolio (Projects Phoenix and Leonis) and a new frontier opportunity in Namibia, positioning it as a pure-play exploration entity with significant potential upside contingent on drilling success.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


DuPont De Nemours, Inc. (NYSE: DD) To Separate Its Electronics Business on Nov 1

By Garvit Bhandari

  • DuPont will separate its Electronics unit as Qnity Electronics Inc. on Nov 1, 2025, creating two focused platforms – a high-growth semiconductor materials business and a steadier diverfied industrial company
  • Qnity launches with ~$4.3B sales, ~29% margins, strong semiconductor exposure but higher leverage and cyclicality
  • We value Qnity at $106/share (17.2× FY26E EBITDA) and DuPont (ex-Qnity) at $47.5/share (13.0× FY26E EBITDA).

Ercros: Regulatory Green Light, Shareholder Hurdles Ahead

By Jesus Rodriguez Aguilar

  • CNMC approval with commitments de-risks the regulatory leg, shifting focus to shareholder acceptance and the Ministry’s decision; the spread has compressed but still offers short-dated, event-driven upside.
  • Ercros’s weak H1 performance and cyclical trough distort multiples; the €3.505 offer equates to ~9x EBITDA today but nearer 6× on normalized levels, consistent with control transaction benchmarks.
  • Base-Case IRR exceeds 100% annualized if settled by December; downside anchored by €2.56 break price, while any price bump toward €4.40 adds optionality without being part of the base case.

Primer: Yunnan Yuntianhua Co A (600096 CH) – Oct 2025

By αSK

  • Yunnan Yuntianhua is a leading state-owned enterprise in China’s fertilizer and chemical sector, possessing significant competitive advantages through its vertical integration and access to vast phosphate rock reserves in Yunnan province.
  • The company demonstrates strong financial performance with robust cash flow generation and an attractive dividend yield, though its revenue and earnings are subject to the cyclical nature of commodity markets.
  • Future growth is anticipated to be driven by strategic expansion into new energy materials, such as iron phosphate, and a continued focus on high-value fine chemical products, alongside strengthening its market position in Southeast Asia.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


bp — bp updates Bumerangue

By Edison Investment Research

bp has provided an update on its hydrocarbon discovery at the Bumerangue block in the pre-salt Santos Basin, offshore Brazil. While the find was first reported in August, yesterday’s confirmation of a c 1,000-metre gross hydrocarbon column, comprising around 100 metres of oil and 900 metres of liquids-rich gas condensate, adds clarity on scale and composition. Liquids are present across the full column. bp reports high-quality rock properties and, significantly, indicates that it believes that the carbon dioxide content in the reservoir can be managed. Although still at an early stage of evaluation, visible progress at Bumerangue is encouraging given its potential scale and its emerging significance within bp’s upstream growth pipeline.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Macro: HEW: Cautious Committees and more

By | Daily Briefs, Macro

In today’s briefing:

  • HEW: Cautious Committees
  • The Art of the Trade War: U.S. ON THE HAMSTER WHEEL!
  • Rising Domestic Pull And Price Strength Reshape Cambodian Rubber
  • When the Boom Bites Back: How a Global LNG Surge Could Reshape U.S. Gas Markets
  • Walker’s Weekly: Dr. Jim’s Summary of Key Global Macro Developments – 31 Oct 2025
  • Oil futures: Crude drifts as US-China talks, OPEC+ eyed
  • CX Daily: China’s AI Companions Struggle to Turn Intimacy Into Industry


HEW: Cautious Committees

By Phil Rush

  • Central bankers broadly delivered on expectations this week, while cautioning that changes will likely be less than markets assume. The BOJ and ECB were also cautious.
  • Flash EA inflation slowed, as expected, but services and core stoked hawkish pressure, while money and credit data in the EA and UK show accommodation of inflation.
  • Next week’s BoE decision is no longer priced as a forgone conclusion, but the case to cut is weak. Like its peers, the BoE should cautiously damp dovish expectations.

The Art of the Trade War: U.S. ON THE HAMSTER WHEEL!

By David Mudd

  • The much hyped meeting between the presidents of the world’s two largest economies fell short of global expectations.  Key issues were only delayed, not resolved.
  • China has been steadfast in the face of U.S. hardball tactics, resulting in the U.S. reversal of announced measures, like the expansion of the restricted entity list. 
  • The effective tariff rate on Chinese exports to the U.S. will be approximately 30%, which  is 20% higher than when President Trump took office.

Rising Domestic Pull And Price Strength Reshape Cambodian Rubber

By Vinod Nedumudy

  • Export volumes fall, but revenues hold firm on higher prices  
  • Domestic latex consumption surges 89%, reshaping local demand base  
  • Chinese investments deepen industrial linkages and energy synergy

When the Boom Bites Back: How a Global LNG Surge Could Reshape U.S. Gas Markets

By Suhas Reddy

  • Henry Hub prices are rising ahead of a colder U.S. winter, but stronger domestic production and expanding LNG exports could temper the pace of seasonal gains.
  • Global LNG capacity is set to soar by 60% by 2030, raising the risk of a supply glut that could depress international gas prices and challenge U.S. competitiveness.
  • While global LNG oversupply may pressure prices abroad, surging AI-driven electricity demand and slower renewable deployment could lift domestic gas consumption and keep prices resilient.

Walker’s Weekly: Dr. Jim’s Summary of Key Global Macro Developments – 31 Oct 2025

By Dr. Jim Walker

  • Bank of Japan (BoJ): BoJ kept rates unchanged at 0.5%, despite 3% inflation — a clear policy mismatch.
  • Federal Reserve (US): The Fed cut rates despite inflation running above target (≈3.6% annualized).
  • China: Industrial profits up 21.6% YoY in September, marking a two-month streak (August: +20.4%).

Oil futures: Crude drifts as US-China talks, OPEC+ eyed

By Quantum Commodity Intelligence

  • Crude oil futures were drifting Thursday after benchmarks were given a midweek uplift from inventory data, although focus was pivoting towards the US-China trade talks and upcoming OPEC+ meeting.
  • Front-month Dec25 ICE Brent futures were trading at $64.92/b (2014 BST) versus Wednesday’s settle of $64.92/b, while Dec25 NYMEX WTI was at $60.46/b against a previous close of $60.48/b.
  • Investors were eyeing the outcome of talks between US President Donald Trump and Chinese leader Xi Jinping, which were expected to at least reduce tensions in the on-again-off-again trade war.

CX Daily: China’s AI Companions Struggle to Turn Intimacy Into Industry

By Caixin Global

  • AI / Analysis: China’s AI Companions Struggle to Turn Intimacy Into Industry
  • China-U.S. /: U.S., China Reach Broad Truce to Ease Trade War
  • Trade /: China Expands Pilot Program for Easier Cross-Border Trade Settlements

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Bio-Thera Solutions Ltd, Establishment Labs Holdings In, Hogy Medical, Alnylam Pharmaceuticals, Olba Healthcare Holdings, Beijing Tongrentang Co A, Guangyuyuan Chinese Herbal Medicn, Jcr Pharmaceuticals and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Quiddity Leaderboard STAR 50/100 Dec25: Final Expectations; New Ideas
  • Primer: Establishment Labs Holdings In (ESTA US) – Oct 2025
  • Hogy (3593 JP): Can Activism Alone Save Hogy From Going Down a Spriral? Fundamentals Don’t Support
  • Alnylam Pharmaceuticals (ALNY US): On Track for S&P500 Inclusion Following Positive Earnings
  • Olba Healthcare Holdings (2689 JP): Q1 FY06/26 flash update
  • Primer: Beijing Tongrentang Co A (600085 CH) – Oct 2025
  • Primer: Guangyuyuan Chinese Herbal Medicn (600771 CH) – Oct 2025
  • JCR Pharmaceutical (4552 JP): Licensing Income Boosts H1FY26 Overall Performance; What Lies Ahead


Quiddity Leaderboard STAR 50/100 Dec25: Final Expectations; New Ideas

By Janaghan Jeyakumar, CFA

  • STAR 50 Index is a tech-focused, blue-chip index in Mainland China which tracks the top 50 largest and most liquid names in the STAR market of the Shanghai Stock Exchange.
  • STAR 100 index tracks the next 100 names (51st-150th ranks) and it represents the mid-cap segment of the STAR market.
  • In this insight, we have presented our final expectations for ADDs and DELs for the upcoming December 2025 index rebal event.

Primer: Establishment Labs Holdings In (ESTA US) – Oct 2025

By αSK

  • Establishment Labs is a medical technology company poised for significant growth following the recent US FDA approval for its flagship Motiva® breast implants, granting access to the world’s largest market for aesthetic procedures.
  • The company’s key competitive advantage lies in its focus on safety and innovation, with its proprietary SmoothSilk® surface and ergonomic implant designs demonstrating low complication rates in extensive clinical studies, potentially disrupting a market dominated by long-standing incumbents.
  • Despite strong revenue growth, the company has a history of significant net losses and negative cash flow. The successful commercialization in the US and a clear path to profitability are critical for future stock performance.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Hogy (3593 JP): Can Activism Alone Save Hogy From Going Down a Spriral? Fundamentals Don’t Support

By Tina Banerjee

  • Hogy Medical (3593 JP) , in the last 10 fiscals, witnessed sales grow at CAGR of 1%. In tandem with that, company reported 4% drop sales to ¥18.9B in H1FY26.
  • The company revised FY26 sales guidance downwards to ¥39.2B (from previous ¥41.8B), with profits also witnessing considerable downward revision.
  • Stock to underperform and so we recommend a SELL on Hogy at this moment. Strategically, two possible outcomes open for Hogy, a take-over by another corporate entity or going private.

Alnylam Pharmaceuticals (ALNY US): On Track for S&P500 Inclusion Following Positive Earnings

By Dimitris Ioannidis

  • Alnylam Pharmaceuticals (ALNY US) just became eligible for S&P500 following positive earnings released on 30 October 2025.
  • The company’s market cap and other eligibility metrics are estimated to place it among the top 5 addition candidates for S&P500 with a higher chance of inclusion in 2026.
  • Top 3 addition candidates for S&P500 are CRH, FIX and PSTG with the next inclusion expected by the end of November following the Omnicom-Interpublic $13bn acquisition.

Olba Healthcare Holdings (2689 JP): Q1 FY06/26 flash update

By Shared Research

  • The company’s Q1 FY06/26 sales were JPY30.8bn (+6.1% YoY), with operating profit at JPY259mn (-7.3% YoY).
  • Medical Devices and Consumables segment sales rose 5.2% YoY, driven by consumables and equipment sales growth.
  • SPD segment sales increased 6.3% YoY, but operating profit declined 31.4% YoY due to rising SG&A expenses.

Primer: Beijing Tongrentang Co A (600085 CH) – Oct 2025

By αSK

  • Unmatched Brand Heritage and Market Leadership: With a history spanning over 350 years, Beijing Tongrentang is a premier brand in Traditional Chinese Medicine (TCM), commanding significant brand loyalty and market recognition. This “time-honored brand”status provides a substantial competitive advantage in a fragmented market.
  • Favorable Industry Tailwinds: The company is well-positioned to benefit from China’s aging population, rising health consciousness, and strong government support for the TCM industry. These demographic and policy trends are expected to drive sustained demand for TCM products and services.
  • Concerning Cash Flow Trend Despite Solid Growth: While the company has demonstrated consistent revenue and net income growth, a significant and persistent decline in operating and free cash flow over the past several years raises concerns about working capital management and the quality of earnings.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


Primer: Guangyuyuan Chinese Herbal Medicn (600771 CH) – Oct 2025

By αSK

  • Venerable Brand with Deep Heritage: Guangyuyuan is one of China’s oldest Traditional Chinese Medicine (TCM) brands, founded in 1541. This long history provides significant brand equity and consumer trust, a key advantage in the healthcare sector. The company was officially recognized as a “China Time-Honored Brand”by the Ministry of Commerce in 2006.
  • Favorable Industry Tailwinds: The TCM industry in China is experiencing robust growth, supported by government policies, an aging population, and increasing health awareness. The market is projected to grow at a double-digit CAGR, creating a favorable environment for established players like Guangyuyuan.
  • Financial Turnaround and Growth Focus: After a significant loss in 2022, the company has demonstrated a strong recovery in profitability through 2023 and 2024. Management is focused on a growth-oriented strategy, emphasizing product innovation and new marketing channels, including e-commerce and collaborations with influencers.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


JCR Pharmaceutical (4552 JP): Licensing Income Boosts H1FY26 Overall Performance; What Lies Ahead

By Tina Banerjee

  • Jcr Pharmaceuticals (4552 JP) has reported in-line performance for H1FY26. While mainstay product is facing pricing and competitive pressure, one-off licensing income has driven overall performance.   
  • JCR is expected to meet FY26 guidance. H1FY26 sales, operating profit, and net profit represent progress rate of 56.5%, 91.5%, and 57.0%, against full-year guidance, respectively.
  • Heavy dependence on one major product, which is subject to pricing and competitive pressure, and no major product launch lined up anytime soon are key near-term risks.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief TMT/Internet: Mediatek Inc, Global Testing Corp, Golden Matrix Group Inc, Hakuto Co Ltd, Avant Corp, I Net Corp, JNTC , Logizard, iHeartMedia and more

By | Daily Briefs, TMT/Internet

In today’s briefing:

  • MediaTek (2454.TT): 4Q25 GM Eases on Mix; 2025 Record Revenue; 2026 AI Upswing Begins
  • Primer: Global Testing Corp (GTC SP) – Oct 2025
  • GMGI: 3Q25 First Look Record Quarterly Revenue Results
  • Hakuto Co Ltd (7433 JP): 1H FY03/26 flash update
  • Avant Corp (3836 JP): Q1 FY06/26 flash update
  • I Net Corp (9600 JP): 1H FY03/26 flash update
  • Primer: JNTC (204270 KS) – Oct 2025
  • (30 Oct 2025) Logizard(4391 JP) — Fisco Company Research
  • Primer: iHeartMedia (IHRT US) – Oct 2025


MediaTek (2454.TT): 4Q25 GM Eases on Mix; 2025 Record Revenue; 2026 AI Upswing Begins

By Patrick Liao

  • 4Q25 Guidance: Revenue is NT$142.1 – 150.1 bn (+0 – 6% QoQ, +3 – 9% YoY); Gross margin is 46% ± 1.5ppt; Opex ratio is 31% ± 2ppt.
  • Cloud ASIC TAM: Raised from US$40bn → ≥ US$50bn by 2028; MediaTek targeting ≥ 10–15% share; Gross Margin: 4Q dip from mix; 2026 to benefit from repricing + high-value allocation
  • MediaTek continues to execute on a dual-engine AI strategy. Despite near-term margin pressure from mix and FX, the company is building a foundation for sustainable profit growth.

Primer: Global Testing Corp (GTC SP) – Oct 2025

By αSK

  • Global Testing Corp (GTC) is an established Outsourced Semiconductor Assembly and Test (OSAT) provider, specializing in testing services for logic and mixed-signal semiconductors. Headquartered in Taiwan, the company is strategically positioned within the global semiconductor hub.
  • The company is poised to benefit from positive long-term industry trends, including the proliferation of AI, IoT, 5G, and automotive electronics, which are driving demand for more complex and rigorous semiconductor testing. The OSAT market is projected to grow at a CAGR of 5-9% over the next several years.
  • Despite a challenging recent period marked by declining net income and margins, the company maintains a strong balance sheet with minimal debt. However, its revenue and profit trajectory in the near term will be highly dependent on the cyclical nature of the semiconductor industry and its ability to secure its position with key customers.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


GMGI: 3Q25 First Look Record Quarterly Revenue Results

By Zacks Small Cap Research

  • Zacks Small-Cap Research Note for Golden Matrix Group (GMGI)

Hakuto Co Ltd (7433 JP): 1H FY03/26 flash update

By Shared Research

  • 1H FY03/26 results: Sales JPY83.8bn (-6.7% YoY), Operating profit JPY2.3bn (-41.6% YoY), Net income JPY2.0bn (-22.1% YoY).
  • Sales in automotive applications fell 9.5% YoY to JPY64.2bn, with segment profit down 59.9% YoY.
  • Full-year forecast for FY03/26: Sales JPY186.0bn (+1.6% YoY), Operating profit JPY6.0bn (-24.2% YoY), Net income JPY4.9bn (-4.5% YoY).

Avant Corp (3836 JP): Q1 FY06/26 flash update

By Shared Research

  • Revenue increased to JPY7.5bn (+10.9% YoY), driven by strong investment demand and growth in key business segments.
  • Operating profit rose to JPY1.3bn (+22.8% YoY), with improved margins due to software business growth and reduced outsourcing costs.
  • Order backlog in Q1 FY06/26 was JPY5.5bn (+15.7% YoY), despite varying revenue and profit growth across business segments.

I Net Corp (9600 JP): 1H FY03/26 flash update

By Shared Research

  • Revenue reached JPY20.4bn (+7.9% YoY), operating profit JPY1.4bn (+34.6% YoY), net income JPY775mn (-23.3% YoY).
  • Information processing services revenue rose 9.0% YoY to JPY8.2bn, with gross profit up 15.1% YoY.
  • System development services revenue increased 6.3% YoY to JPY11.1bn, gross profit rose 16.7% YoY to JPY2.6bn.

Primer: JNTC (204270 KS) – Oct 2025

By αSK

  • JNTC is a technology leader in specialized glass processing, transitioning from a volatile mobile component supplier to a high-growth solutions provider for next-generation industries, including foldable displays, automotive, and AI semiconductor packaging.
  • The company’s strategic pivot to Ultra-Thin Glass (UTG) for foldables and Through Glass Via (TGV) substrates for AI chips offers a significant runway for growth, with revenue expected to double in the coming years. This expansion into high-margin sectors is a key catalyst for re-rating.
  • Despite the promising outlook, investors must consider the high degree of operational and financial risk, evidenced by historically volatile revenue and profitability, significant customer concentration, and weak gross margins in its legacy businesses.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


(30 Oct 2025) Logizard(4391 JP) — Fisco Company Research

By FISCO

Key points (machine generated)

  • Logizard Co., Ltd. reported a 10.1% increase in net sales to ¥2,177 million and a 17.8% rise in operating profit to ¥408 million for FY6/25, driven by cloud services.
  • The company focuses on inventory management systems for retail and logistics, offering subscription-based solutions like Logizard ZERO and Logizard OCE.
  • For FY6/26, Logizard expects a 12.1% increase in net sales but a decline in operating profit due to investments, aiming for significant growth by FY6/28.

This article is sourced from an online content aggregator through publicly available sources and is displayed below for general informational purposes only.


Primer: iHeartMedia (IHRT US) – Oct 2025

By αSK

  • iHeartMedia possesses an unparalleled reach in the U.S. audio market through its extensive portfolio of over 850 broadcast radio stations, complemented by a rapidly growing digital audio segment that includes the iHeartRadio app and a leading podcast network.
  • The company is burdened by a highly leveraged balance sheet, with approximately $5.2 billion in total debt, posing significant financial risk and constraining its flexibility, especially with substantial debt maturities looming.
  • Management’s strategic focus is on offsetting the secular decline in traditional radio advertising by accelerating growth in the Digital Audio Group, particularly in podcasting, and implementing significant cost-saving measures, including the use of AI, to improve profitability.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: SK D&D Co Ltd, Hokkoku Financial Holdings, Strike, Financial Products Group Co, Foxtons, Gentera SAB De CV and more

By | Daily Briefs, Financials

In today’s briefing:

  • SK D&D: Delisting Tender Offer by Hahn & Co Fails – What’s Next?
  • Hokkoku Financial Holdings (7381 JP): 1H FY03/26 flash update
  • Strike (6196 JP): Full-year FY09/25 flash update
  • Financial Products Group Co (7148 JP): Full-year FY09/25 flash update
  • Hybridan Small Cap Feast: 23 October 2025
  • Primer: Gentera SAB De CV (GENTERA* MM) – Oct 2025


SK D&D: Delisting Tender Offer by Hahn & Co Fails – What’s Next?

By Douglas Kim

  • SK D&D announced the results of the delisting tender offer by Hahn & Co. SK &D mentioned that the subscription reached only 40% of the planned tender offer amount.
  • Post failed tender offer for SK D&D by Hahn & Co, we expect this to have a positive impact on SK D&D’s share price.
  • The major reason for this is that there are still many investors that believe that SK D&D’s shares are significantly undervalued at P/B of only 0.4x.

Hokkoku Financial Holdings (7381 JP): 1H FY03/26 flash update

By Shared Research

  • Consolidated ordinary income increased by 19.6% YoY to JPY53.7bn, driven by higher interest and dividend income.
  • Hokkoku Bank’s core gross profit grew 23.9% YoY to JPY24.5bn, with a 50.0% rise in core operating profit.
  • Non-performing loans at Hokkoku Bank totaled JPY78.3bn, with a 0.25pp YoY decline in percentage of total credit.

Strike (6196 JP): Full-year FY09/25 flash update

By Shared Research

  • FY09/25 revenue was JPY20.3bn (+12.0% YoY), with operating profit at JPY6.3bn (-6.5% YoY) and net income JPY4.7bn (-4.7% YoY).
  • Strike forecasts FY09/26 revenue of JPY24.3bn (+19.8% YoY) and operating profit of JPY8.4bn (+32.2% YoY).
  • The company plans an annual dividend of JPY180.0 per share, maintaining a payout ratio of 60.2%.

Financial Products Group Co (7148 JP): Full-year FY09/25 flash update

By Shared Research

  • FY09/25 revenues reached JPY129.7bn (+20.4% YoY), with operating profit at JPY25.4bn (-11.2% YoY), and net income JPY18.1bn (-11.2% YoY).
  • Leasing Fund Business saw JPY233.2bn equity placement (+26.5% YoY), while Domestic Real Estate Fund revenue was JPY95.9bn (+27.8% YoY).
  • FY09/26 forecasts include JPY130.5bn revenue (+0.6% YoY), JPY30.4bn operating profit (+19.6% YoY), and JPY21.0bn net income (+15.7% YoY).

Hybridan Small Cap Feast: 23 October 2025

By Hybridan

  • Chapel Down Group 40p £60m (CDGP.L) The wine company announced the completion of its 2025 harvest from it’s 1,018 acres of vineyards of which 777 are fully productive, an increase of +30% productive vineyards since 2022.
  • This year’s yield is expected to be 2,882 tonnes (2024: 1,852 tonnes), at an average yield of 3.7 tonnes per acre (2024: 2.5 tonnes per acre), which is +15% higher than the historic 5-year average yield per tonne.
  • The warm and consistent summer of 2025 created optimal conditions for fruit development, resulting in grapes with a good balance of ripe fruit flavours for complexity and texture with the natural acidity that will add a fresh, crisp backbone to the company’s wines. 

Primer: Gentera SAB De CV (GENTERA* MM) – Oct 2025

By αSK

  • Market Leader in a Structurally Growing Niche: Gentera is a dominant player in the Mexican and Peruvian microfinance sectors, targeting a large, underserved market of micro-entrepreneurs and lower-income individuals. This focus on financial inclusion provides a long runway for growth, driven by both economic development and the formalization of the economy.
  • Robust Financial Performance and Growth Trajectory: The company has demonstrated a strong track record of revenue and net income growth, with 3-year CAGRs of 22.5% and 36.8%, respectively. This performance is underpinned by a highly profitable business model with ample net interest margins and a post-pandemic recovery in loan origination and credit quality.
  • Strategic Focus on Digital Transformation: Management is committed to a digital transformation strategy aimed at serving more customers more efficiently. This focus on digitalization is expected to enhance operational leverage, improve customer experience, and solidify its competitive position against traditional banks and emerging fintech players.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Uni-Charm Indonesia Tbk PT, Softcare, Lenskart Solutions, Pop Mart, Yellow Hat Ltd, Hang Seng Index, JAKKS Pacific , Croma Security Solutions Group and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Unicharm Indonesia: 3rd Quarter Results: Bit Disappointing But
  • Softcare Pre-IPO: Decent Cornerstones, Riding on Africa Growth
  • Leskart Solutions IPO- Covered-Up Deal?
  • Pop Mart (9992.HK): Options Activity Builds as the Rally Cools
  • Yellow Hat Ltd (9882 JP): 1H FY03/26 flash update
  • Hong Kong Single Stock Options Weekly (Oct 27 – 31): Market Cools After Busy News Week
  • JAKK: 3Q Review: Taking Safer Route in an Unsure World; Reiterate Buy, $30 PT
  • Croma Security Solutions Group PLC – Friday Take Away: 24 October 2025


Unicharm Indonesia: 3rd Quarter Results: Bit Disappointing But

By Punit Khanna

  • Company incurred a loss of 90 bn Rupiah in 3rq quarter or loss of 21.6 Rupiah per share. 
  • Even though sales have declined for the first 9 months – inventory and receivables have increased indicating stress in working capital. 
  • GP Margin is flat, selling expense as %ge of sales have increased as we think company is pushing economy products to compete with local players and maintain market share

Raising Money for Persons with Disabilities in Singapore

For your kind consideration

This report has been prepared by Vriddhi Consulting, founded by Punit and Debjani Khanna. A portion of the research was contributed by Shubham Khanna, an individual on the autism spectrum.  We are grateful to Smartkarma for providing a platform to share this research and amplify its impact.

All proceeds from the publication of this report will be donated to support people with disabilities in Singapore. If you find this report valuable, we invite you to support our campaign, “Raising Money for Persons with Disabilities in Singapore.” Every contribution directly benefits the Goh Chok Tong Enable Fund and qualifies for a 250% tax deduction for Singapore tax residents.

To contribute, please visit this URL. 


Softcare Pre-IPO: Decent Cornerstones, Riding on Africa Growth

By Nicholas Tan

  • Softcare (SOFT HK) is looking to raise up to US$307m in its upcoming Hong Kong IPO.
  • It is an international hygiene product corporation with a focus on fast-growing Emerging Markets including Africa, Latin America and Central Asia. 
  • In this note, we examine the IPO dynamics, and look at the firm’s valuation.

Leskart Solutions IPO- Covered-Up Deal?

By Nitin Mangal

  • Lenskart Solutions (0370405Z IN) much-awaited IPO, comprising a fresh issue of INR 21.5 bn and offer for sale of 127.5 mn shares, is set to open for subscription this week.
  • We also find it surprising to note that the company purchased Dealskart, a profitable company with EBITDA of INR 2.33 bn for an insignificant sum of INR 20 mn.   
  • Company was able to report in FY25 is mainly on account of “Other Income” by accounting for gains from lower deferred consideration to boost its Profitability.

Pop Mart (9992.HK): Options Activity Builds as the Rally Cools

By John Ley

  • Pop Mart options recently began trading on HKEX and have gained considerable traction, ranking in the top 10 of volume traded.
  • Pop Mart has had a tremendous rally but is in the midst of a double-digit slump.
  • Option volumes have been skewed, and we outline how best to approach hedging in this environment.

Yellow Hat Ltd (9882 JP): 1H FY03/26 flash update

By Shared Research

  • In 1H FY03/26, sales increased 14.5% YoY to JPY79.3bn, with operating profit rising 2.8% YoY to JPY5.5bn.
  • Gross profit grew 15.0% YoY to JPY35.0bn, while SG&A expenses increased 17.6% YoY to JPY29.5bn.
  • The company had 921 domestic stores by end-Q2 FY03/26, with six openings and three closings in Japan.

Hong Kong Single Stock Options Weekly (Oct 27 – 31): Market Cools After Busy News Week

By John Ley

  • Busy news week with trade and deal headlines taking center stage.
  • Stock have been treading water aside from the Materials Sector with breadth reversing from last week’s rebound.
  • The thick of earnings season is past with only 15 companies reporting in the next week.

JAKK: 3Q Review: Taking Safer Route in an Unsure World; Reiterate Buy, $30 PT

By Small Cap Consumer Research

  • We are reiterating our Buy rating and $30 price target for JAKKS Pacific after the company reported 3Q25 (September) results even worse than our “doomsday” scenario, as domestic revenue fell 40%, driven by uncertainty over tariffs and push back and cancelation of Freight on Board (“FOB”) orders for the start of the Holiday season.
  • While JAKKS management once again did a strong job of controlling expenses, it was not enough against a 34% YoY revenue decline.
  • Further, management reiterated their decision to remain focused on the FOB model and to not take material inventory risks in 4Q.

Croma Security Solutions Group PLC – Friday Take Away: 24 October 2025

By Hybridan

  • Friday Takeaway from UK Small Caps This will delve a little deeper on individual companies and focus on non-house stocks under £200m market capitalisation to raise awareness 24th October 2025 Alphabetically arranged Share prices and market capitalisations taken from Alpha Terminal from the current price on the day of publication.
  • Top three shareholders are taken from the websites of the companies that we are writing about, unless there is a more up to date TR-1 notification RNS announcement.
  • Recent updates show these businesses are moving forward which could be highlighted when results are published.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Most Read: Mayne Pharma, Nidec Corp, Ibiden Co Ltd, Mandom Corp, ICICI Bank Ltd, Sejin Heavy Industries Co Ltd, Sumitomo Densetsu, Brainpad Inc, SK Square and more

By | Daily Briefs, Most Read

In today’s briefing:

  • Mayne Disagrees With Cosette On MAC
  • Nikkei 225 Index Rebalance: 🚨Ibiden (4062 JP) To Replace Nidec (6594 JP) 🚨
  • [Japan Special] Ibiden (4062) Replaces Nidec (6594) In Nikkei 225 on Accounting – A VERY BIG DEAL
  • [Japan Activism] Mandom (4917 JP) MBO Sees Murakami Pushing Harder, Now at 16.59%
  • NIFTY Bank Index: Methodology Changes to Result in Big Flows
  • Another Passive Flow Trading Target Identified: Sejin Heavy in the Dec Shipbuilding ETF Rebal
  • [Japan M&A] Daiwa House Buyout of Sumitomo Densetsu (1949 JP) At ¥9,760 – A Good Exit
  • [Japan M&A] Fujitsu Buys Out Brainpad (3655) At Near 100% Premium
  • Intel on Today’s SK Square Price Action: Rotation Flow Triggered by Hynix’s 10% Fund Cap Removal
  • HEW: Cautious Committees


Mayne Disagrees With Cosette On MAC

By David Blennerhassett

  • As widely speculated, Cosette asserted to Mayne Pharma (MYX AU) on the 17th May a Material Adverse Change (MAC) has occurred.
  • Mayne disagrees, and views the pre-requisites for a MAC, as defined in the SID, have not been established. 
  • What now? The Scheme is not terminated. Both parties remain in consultation. If those talks are not satisfactory (say, a price reduction [my guess]), Cosette said it will walk. 

Nikkei 225 Index Rebalance: 🚨Ibiden (4062 JP) To Replace Nidec (6594 JP) 🚨

By Brian Freitas


[Japan Special] Ibiden (4062) Replaces Nidec (6594) In Nikkei 225 on Accounting – A VERY BIG DEAL

By Travis Lundy

  • In June, Nidec Corp (6594 JP) announced they would delay the release of their yuho for three months because of an internal investigation into NIDEC FIR INTERNATIONAL (Italy).
  • In September they launched a special committee. Shares fell 22%. Last Thursday, the company cancelled its interim dividend. Today, the JPX designated Nidec as Security on Special Alert.
  • This is a VERY BIG DEAL. Nikkei225 deletes Nidec 5-Nov-2025, replaced by Ibiden Co Ltd (4062 JP) (PAF 1.0x). Designation also triggers TOPIX deletion for Nidec, likely on 30 October. 

[Japan Activism] Mandom (4917 JP) MBO Sees Murakami Pushing Harder, Now at 16.59%

By Travis Lundy

  • Four weeks ago, CVC announced a family-led MBO of hair care and cosmetics company Mandom Corp (4917 JP) at a price which was decidedly too light, well below company plans.
  • One activist wrote a letter clearly calling them out for accepting a low-ball price well below the Medium Term Management Plan target. Another bought a lot of shares. 
  • On 25 September, Murakami-san and affiliates reported an 8.39% position. Seven trading days later it is 16.59% and the shares are up small from my last piece + 1. 

NIFTY Bank Index: Methodology Changes to Result in Big Flows

By Brian Freitas

  • In May, SEBI recommended changes to the minimum number of constituents for non-benchmark indices and the capping for those indices. Then came the market consultation in August.
  • SEBI has now confirmed the changes along with the timeline for capping changes to the largest stocks in the index.
  • The changes could commence in December and continue till March. The adds will take place in December and weight changes for the largest stocks will take place in 4 tranches.

Another Passive Flow Trading Target Identified: Sejin Heavy in the Dec Shipbuilding ETF Rebal

By Sanghyun Park

  • HHI–Mipo merger overlaps Dec review: Mipo dropped Nov 26, desk holds cash, rebal Dec 12, new HHI shares list Dec 15 but capped at 10%.
  • No ad-hoc replacement for Mipo Nov 26; Dec review will add a new name, likely Sejin Heavy (075580 KS), with no other significant flows flagged.
  • Sejin Heavy’s recent post-rally volume cools; passive inflow ~1.5x DTV may trigger visible price action, with potential front-running 1–2 days ahead of Dec 12 ETF rebal.

[Japan M&A] Daiwa House Buyout of Sumitomo Densetsu (1949 JP) At ¥9,760 – A Good Exit

By Travis Lundy


[Japan M&A] Fujitsu Buys Out Brainpad (3655) At Near 100% Premium

By Travis Lundy

  • Today after the close, Fujitsu Ltd (6702 JP), with 110,000 employees, announced a buyout of a small “labour-intensive” AI/ML sysdev business with 200+ data scientists.
  • Brainpad Inc (3655 JP) is being bought out from its co-founders and others at a near-100% premium. Not an all-time high, but not a low price.
  • Somewhat heavily shorted, this will trade tight, but I expect nobody will come over the top. 

Intel on Today’s SK Square Price Action: Rotation Flow Triggered by Hynix’s 10% Fund Cap Removal

By Sanghyun Park

  • KOFIA says Hynix hit 10.89% weight in October vs 8.37% in September, lifting the 10% fund cap — now local funds can size up like Samsung Electronics.
  • SK Square might have been dumped today as locals unwound proxy trades; with Hynix freed from the 10% cap, funds rotated directly into Hynix, front‑running the shift.
  • Key now is rotation size; SK Square’s beta‑plus trade to Hynix is fading, and near term we should expect relative underperformance as flows migrate.

HEW: Cautious Committees

By Phil Rush

  • Central bankers broadly delivered on expectations this week, while cautioning that changes will likely be less than markets assume. The BOJ and ECB were also cautious.
  • Flash EA inflation slowed, as expected, but services and core stoked hawkish pressure, while money and credit data in the EA and UK show accommodation of inflation.
  • Next week’s BoE decision is no longer priced as a forgone conclusion, but the case to cut is weak. Like its peers, the BoE should cautiously damp dovish expectations.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Analytics and News
  • ✓ Events & Webinars



Daily Brief Quantitative Analysis: HSCEI Index Earning Revision (Oct): Pop Mart Intl and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • HSCEI Index Earning Revision (Oct): Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM
  • HS TECH Index Earning Revision (Oct): MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd


HSCEI Index Earning Revision (Oct): Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM

By Ke Yan, CFA, FRM

  • We analysed the earning revision of component stocks of HSCEI in the past month.
  • We tabulated stocks with the top impact on index’s EPS, stocks’ EPS revision, and revenue revision.
  • We highlighted EPS revision on Pop Mart Intl, MEITUAN, JD Health, China Life, JD.COM, PING AN INSURANCE, China Life, Ping An, Pop Mart, Meituan, Jd, Jd Health.

HS TECH Index Earning Revision (Oct): MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd

By Ke Yan, CFA, FRM

  • We analysed the earning revision of component stocks of HS TECH in the past month.
  • We tabulated stocks with the top impact on index’s EPS, stocks’ EPS revision, and revenue revision.
  • We highlighted EPS revision on MEITUAN, TME, BIDU, JD.COM, BYD, ASMPT, SENSETIME, Meituan, Jd, BYD, Bidu, Sensetime, Tme, Asmpt.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ESG: Is TSE List Effective? Companies Need to Demonstrate Momentum in Raising Their Capital Profitability and more

By | Daily Briefs, ESG

In today’s briefing:

  • Is TSE List Effective? Companies Need to Demonstrate Momentum in Raising Their Capital Profitability


Is TSE List Effective? Companies Need to Demonstrate Momentum in Raising Their Capital Profitability

By Aki Matsumoto

  • For investors targeting large-cap companies, improvements in ROE and P/B are almost expected. However, for the majority of smaller-cap companies, such improvements have not yet reached a visible level.
  • Lately, while P/B of companies with low market capitalization is rising, ROE growth remains sluggish. If ROE remains slow, support from BoJ’s continued monetary easing policy must play significant role.
  • It is unreasonable to expect investors to take an interest solely through IR outreach without providing evidence that signals change within the company or convinces investors that change is imminent.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars